Astellas has signed an R&D and licensing deal with Kelonia Therapeutics that aims to develop CAR-T therapies for cancer that will push the boundaries of what can be ac
Japan’s Astellas has named Nick Eshkenazi to the new role of chief digital and transformation officer (CTDO), the first time it has included a digital role in its top mana
Stellar results in a bladder cancer study have prompted Astellas to raise its peak sales prediction for Pfizer-partnered antibody-drug conjugate Padcev, although its new m
A thriving start-up ecosystem is essential to the health of the modern life sciences industry, as it provides an incubator for innovative ideas that might be too high-risk for larger, more
The EMA’s human medicines committee refused marketing approvals for two drugs from Neuraxpharm and Apellis at its January meeting, but both companies have said they will a
Manufacturing problems have scuppered Astellas’ chances of approval in the US this month for zolbetuximab, currently leading the field among Claudin 18.2-targeted drug can